bluebird bio Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
20,181.00
25,421.00
14,079.00
6,155.00
35,427.00
54,579
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
15,065.00
18,043
Gross Income
-
-
-
-
20,362.00
36,536
SG&A Expense
44,187.00
81,573.00
172,828.00
260,246.00
353,052.00
605,560
EBIT
24,947.00
60,380.00
166,168.00
263,739.00
332,690.00
569,024
Unusual Expense
440.00
246.00
2,869.00
4,091.00
525.00
2,999
Non Operating Income/Expense
37.00
32.00
723.00
3,711.00
1,267.00
1,961
Interest Expense
-
-
-
-
2,001.00
-
Pretax Income
25,321.00
60,506.00
166,723.00
264,119.00
335,433.00
555,438
Income Tax
-
11,797.00
60.00
612.00
210.00
187
Consolidated Net Income
25,321.00
48,709.00
166,783.00
263,507.00
335,643.00
555,625
Net Income
25,321.00
48,709.00
166,783.00
263,507.00
335,643.00
555,625
Net Income After Extraordinaries
25,321.00
48,709.00
166,783.00
263,507.00
335,643.00
555,625
Net Income Available to Common
25,321.00
48,709.00
166,783.00
263,507.00
335,643.00
555,625
EPS (Basic)
2.02
1.83
4.81
7.07
7.71
10.68
Basic Shares Outstanding
12,555.00
26,546.00
34,669.00
37,284.00
43,535.00
52,032
EPS (Diluted)
2.02
1.83
4.81
7.07
7.71
10.68
Diluted Shares Outstanding
12,555.00
26,546.00
34,669.00
37,284.00
43,535.00
52,032
EBITDA
24,006.00
56,152.00
158,749.00
254,091.00
319,152.00
551,866
Non-Operating Interest Income
29.00
152.00
1,591.00
-
-
14,624

About bluebird bio

View Profile
Address
60 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.bluebirdbio.com
Updated 07/08/2019
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.